Management of Steroid-Induced Myopathy

Clinical Management

• The American College of Physicians and other medical societies recommend implementing a steroid-sparing agent concurrently with dose reduction to maintain treatment of the underlying condition, as weakness is significantly related to cumulative steroid dose 1, 2
• Methotrexate should be started at 15 mg weekly with 1 mg/day folic acid supplementation, targeting 25 mg weekly within 3-6 months, according to the Mayo Clinic Proceedings 1, 3
• Azathioprine should be targeted at a dose of 2 mg/kg of ideal body weight in divided doses, starting at 25-50 mg/week with increments of 25-50 mg/week, as recommended by the Mayo Clinic Proceedings 1, 3
• Mycophenolate mofetil should be started at 500 mg twice daily, increasing by 500 mg weekly until reaching 1000 mg twice daily, based on guidelines from the Mayo Clinic Proceedings 1, 3
• For severe or refractory cases, IVIG therapy (1-2 g/kg) may be considered for patients with severe weakness (Grade 3-4) who have inadequate response to corticosteroids, according to Praxis Medical Insights 4
• Pulse methylprednisolone (10-20 mg/kg or 250-1000 mg for 1-5 consecutive days) may be considered for inflammatory myopathies with severe manifestations before transitioning to oral steroids, as recommended by Praxis Medical Insights 2